Immutep Ltd · ASX:IMM
Immutep — Prima BioMed — Shareholder Meeting (November 2015)
25 slides from Immutep's shareholder meeting presentation, Nov 25, 2015
Slide 1: Annual General Meeting CEO Presentation
Prima BioMed Annual General Meeting CEO Presentation November 25, 2015 ASX:PRR; NASDAQ:PBMD
Slide 2: Notice: Forward Looking Statements
Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or cl
Slide 3: 2015 Highlights – a Transformative Year!
2015 Highlights – a Transformative Year! Planning of 2 new trials – EMA scientific advice Announcement of Final CVacTM OS data Ridgeback $15M placement SPP $10M placement Partners beginning trials (GSK and Novartis) New patent filings New Collaborations – NEC/Yamaguchi
Slide 4: We have raised Prima's market profile
We have raised Prima’s market profile Institutional and Improved independent sell-side market interest standing Active marketing of the new Prima story
Slide 5: Our stock is now actively traded in the US
Our stock is now actively traded in the US (million) 16 day 14 per 12 Nasdaq ASX traded 10 shares 6 . Ord 4 Jan-15 Oct-15
Slide 6: Prima attracting institutional grade investors
Prima attracting institutional grade Market cap – now >US$70m Specialist healthcare funds now on register ~30% of stock now held in ADRs % of Prima shares held in ADRs 0% 5% 10% 15% 20% 25% 30% 35%
Slide 7: Le Ler So oe
Ht Le Ler So oe ; & PRIMA BIOMED
Slide 8: Participation at Investor and Industry Events
Participation at Investor and Industry Events Multiple Roadshows Investor JP Morgan Jan 2015 Bioshares July 2015 Meetings Rodman & Renshaw Sep 2015 Leerink Sept 2015 Business AusBiotech Oct 2015 BioEurope Nov 2015 Development Multiple other contacts Scientific ASCO May 2015 SITC Nov 2015 Conferences
Slide 9: Technology
Technology B ‘Ba is ss <2 PRIMA PLONE Da
Slide 10: Immune Checkpoints
Immune Checkpoints Checkpoints are hot – Prof Frédéric Triebel interviewed about LAG-3 in Nature Biotechnology interview – published July 2015 (Volume 15pp673-675) Immune checkpoints are junctions in immune signalling mechanisms between cells where decisions are made – make good targets for therapie
Slide 11: IMP321
IMP321 Soluble dimeric recombinant form of LAG-3 (fusion protein) IMP321 binds to MHC class II on monocytes DC/ monocyte activation induced Leads to T cell expansion and proliferation Highly efficacious in multiple animal models of cancer and infectious disease Shown to be safe, non-immunogenic and
Slide 12: Chemo-Immunotherapy: IMP321
Chemo-Immunotherapy: IMP321 Treatment of cancer cells with chemotherapy, radiotherapy or other drugs will kill off the cells causing tumour debris to be created and antigen release. Adding an APC activator like IMP321 post cancer treatment enhances antigen uptake by APC’s. They then migrate to lymph
Slide 13: Other Applications: IMP321
Other Applications: IMP321 IMP321 can be combined with other immune checkpoint treatments to help drive optimal immune responses to cancer (eg upcoming combo study) IMP321 can be used as an adjuvant in vaccine combination studies where it helps to boost the magnitude of an antigen specific response
Slide 14: Upcoming trials
Upcoming trials AIPAC Ph I Combo pilot
Slide 15: Planned Phase IIb Chemoimmunotherapy in MBC: AIPAC trial
Planned Phase IIb Chemoimmunotherapy in MBC: AIPAC trial Multicentre, randomised, double blind, placebo-controlled 15 + 196 patients: IMP321 + paclitaxel vs. paclitaxel + placebo Primary objective: efficacy (as Progression-Free Survival) Scientific advice from EMA received in July 2015 Trial initiat
Slide 16: Planned Phase I Study in Immuno-Oncology Combination
Planned Phase I Study in Immuno-Oncology Combination Multicentre, open label, dose escalation Up to 30 patients with unresectable or metastatic melanoma IMP321 + Anti-PD-1 combination study Primary objective: safety, tolerability Trial initiation expected in Q1 2016
Slide 17: Major Addressable Markets in MBC
Major Addressable Markets in MBC
Slide 18: Metastatic Breast Cancer
Metastatic Breast Cancer Annual global incidence of 1.67M new cases of all breast cancer Standard of care is variable but includes hormone therapy, chemotherapy and targeted therapies. We are specifically targeting Her2- cancer; refractory to hormone therapy. Five year survival rate is 22% (American
Slide 19: Partnership Updates
Partnership Updates <2 PRIMA BIOMED :
Slide 20: IMP731
IMP731 for Autoimmune Diseases GSK’s investigational product, GSK2831781, which is derived from IMP731 antibody, aims to kill the few activated LAG- 3+ T cells that are auto-reactive in autoimmune disease leading to long term disease control without generalised immune suppression GlaxoSmithKline hol
Slide 21: IMP701: Antagonist mAb
IMP701: Antagonist mAb IMP701 is an anti-LAG-3 antibody that blocks LAG- 3-mediated immune down-regulation LAG-3 is a prime target for immune checkpoint blockade as it is readily expressed at a high level in many human tumours. Novartis holds exclusive WW rights Aug 2015: Start of Phase 1 study by N
Slide 22: Other Partnerships
Other Partnerships Eddingpharm NEC/ Yamaguchi University Neopharm for CVac R&D to support new patent filings CRO and data managers for clinical trials
Slide 23: Upcoming Milestones
Upcoming Milestones Clinical Q4 2015: Initiation of AIPAC (metastatic breast cancer) // First data in 2016 (e.g. safety/PK) Q1 2016: Initiation of Anti-PD-1 combination Phase I study (melanoma) // First data in 2016(e.g. safety/PK) Expected commencement of Phase II study with IMP731 (GSK) Continued
Slide 24: A solid foundation
A solid foundation Hot Space Institutional Investment First class partnerships Experienced global team Robust science
Slide 25: Thank you!
NASDAQ: PBMD, ASX: PRR Thank you!